ID   Mel290
AC   CVCL_C304
SY   MEL290; Mel-290; Mel 290; MEL 290
DR   CLDB; cl7222
DR   cancercelllines; CVCL_C304
DR   Cell_Model_Passport; SIDM01792
DR   Cosmic; 916141
DR   Cosmic; 1628406
DR   Cosmic; 1669125
DR   DepMap; ACH-002016
DR   ICLC; HTL12002
DR   Wikidata; Q54905165
RX   PubMed=16772116;
RX   PubMed=22236444;
RX   PubMed=22383533;
RX   PubMed=23849826;
RX   PubMed=28018010;
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   From: Ksander B.; Schepens Eye Research Institute; Boston; USA.
CC   Derived from site: In situ; Eye, uvea; UBERON=UBERON_0001768.
ST   Source(s): DepMap; ICLC; PubMed=22236444
ST   Amelogenin: X
ST   CSF1PO: 10,11
ST   D13S317: 8,11
ST   D16S539: 11,13
ST   D18S51: 14,15
ST   D21S11: 28,32.1
ST   D3S1358: 15,18
ST   D5S818: 10,12
ST   D7S820: 11,12
ST   D8S1179: 11,13
ST   FGA: 18,20
ST   Penta D: 10,11
ST   Penta E: 5,8
ST   TH01: 6,9
ST   TPOX: 8,11
ST   vWA: 14,16
DI   NCIt; C7712; Uveal melanoma
DI   ORDO; Orphanet_39044; Uveal melanoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   Age unspecified
CA   Cancer cell line
DT   Created: 22-10-12; Last updated: 05-10-23; Version: 17
//
RX   PubMed=16772116; DOI=10.1016/j.cancergencyto.2005.11.016;
RA   White J.S., Becker R.L., McLean I.W., Director-Myska A.E., Nath J.;
RT   "Molecular cytogenetic evaluation of 10 uveal melanoma cell lines.";
RL   Cancer Genet. Cytogenet. 168:11-21(2006).
//
RX   PubMed=22236444; DOI=10.1111/j.1755-148X.2012.00971.x;
RA   Griewank K.G., Yu X.-X., Khalili J., Sozen M.M., Stempke-Hale K.,
RA   Bernatchez C., Wardell S., Bastian B.C., Woodman S.E.;
RT   "Genetic and molecular characterization of uveal melanoma cell
RT   lines.";
RL   Pigment Cell Melanoma Res. 25:182-187(2012).
//
RX   PubMed=22383533; DOI=10.1158/1535-7163.MCT-11-0676;
RA   Dutton-Regester K., Irwin D., Hunt P., Aoude L.G., Tembe V.,
RA   Pupo G.M., Lanagan C., Carter C.D., O'Connor L., O'Rourke M.,
RA   Scolyer R.A., Mann G.J., Schmidt C.W., Herington A., Hayward N.K.;
RT   "A high-throughput panel for identifying clinically relevant mutation
RT   profiles in melanoma.";
RL   Mol. Cancer Ther. 11:888-897(2012).
//
RX   PubMed=23849826; DOI=10.1016/j.ejca.2013.06.011;
RA   Amaro A., Mirisola V., Angelini G., Musso A., Tosetti F.I.,
RA   Esposito A.I., Perri P., Lanza F.B., Nasciuti F., Mosci C., Puzone R.,
RA   Salvi S., Truini M., Poggi A., Pfeffer U.;
RT   "Evidence of epidermal growth factor receptor expression in uveal
RT   melanoma: inhibition of epidermal growth factor-mediated signalling
RT   by Gefitinib and Cetuximab triggered antibody-dependent cellular
RT   cytotoxicity.";
RL   Eur. J. Cancer 49:3353-3365(2013).
//
RX   PubMed=28018010;
RA   Jager M.J., Bermudez Magner J.A., Ksander B.R., Dubovy S.R.;
RT   "Uveal melanoma cell lines: where do they come from? (an American
RT   Ophthalmological Society thesis).";
RL   Trans. Am. Ophthalmol. Soc. 114:T5-T5(2016).
//